

ADRENERGIC DRUGS - I

I Differences b/w α_1 and α_2 Receptors.

	α_1	α_2
Location	Post-junctional on effector organs	Prejunctional on nerve endings (α_2A) also post-junctional in brain, pancreatic β cells & extra-junctional in certain blood vessels, platelets.
Functions.	Vasoconstriction. Gut smooth muscle contraction Gland-secretion GUT - relaxation eye - contraction of Radial muscles of iris - mydriasis hair - constriction Blood vessels - vasoconstriction Liver - hypoglycemia Heart - Arrhythmia.	Inhibition of Transmitter release Vasoconstriction Used central sympathetic flow. Used endothelial release platelet aggregation
Selective Agonist	Phenylephrine	Clonidine.
Selective Antagonist	Prazosin	Yohimbine.
Coupling Protein	G_q	G_i / G_o

Effector pathway	IP_3 / DAG ↑ Phospholipase A_2 ↑, P _h release	cAMP ↓ K^+ channel ↑ Ca^{2+} channel ↓ or ↑ IP_3 / DAG ↑
------------------	--	---

II Difference b/w β_1 , β_2 , β_3 receptors.

	β_1	β_2	β_3
Location	Heart, J _o cells in kidney	Bronchi, bld vessels, uterus, liver, b _l r, urinary tract, etc	Adipose tissue, Detrusor muscle of bladder.
Selective Agonist	Dobutamine	Salbutamol	Metoprolol.
Selective Antagonist	Metoprolol	α -methyl propranolol	—
Functions	Cardiac stimulations ↑ in force, rate, contraction, velocity, Renin release from kidney	Dilation of arterioles & veins; bronchodilation Intestine } Relax ⁿ uterus } eyes - A _h secretion Lipogenesis; W _h olysis, metabolism, glucagon secretion	Lipolysis Relax detrusor muscle

ADRENERGIC DRUGS-II

① NASAL DECONGESTANTS.

→ Are α_2 receptor agonist which on topical application as dilute solution (0.05 - 0.1%) produce vasoconstriction in nasal mucosa which primarily expresses α receptors.

The imidazoline compounds [xylometazoline and oxymetazoline] are relatively selective α_2 agonists. (like clonidine) with longer duration of action (12 hr) than ephedrine.

After congestion in nasal mucosa is deemed to be less likely than that with ephedrine or phenylephrine. They may cause initial stinging sensation. Regular use of these agents for long periods should be avoided because mucosal ciliary function is impaired; atrophic rhinitis and anosmia can

develop due to persistent vasoconstriction. These drugs can be absorbed from the nose and produce systemic effects, mainly CNS depression and rise in BP.

Nasal decongestants should be used cautiously in hypertensives and in those receiving MAO inhibitors.

② DRUG OF CHOICE IN ANAPHYLACTIC SHOCK. - ADRENALINE (Reasons)

Adrenaline 0.5 mg injected intramuscularly promptly is the DOC in anaphylactic shock. It not only raises BP, but also counteracts bronchospasm and laryngeal edema that may accompany. [Also, Adr should not be injected i.v. (can itself be fatal) unless shock is immediately life threatening. Because of this profile of action as well as rapidity of onset, Adr is the only life saving measure.

③ DRUG OF CHOICE IN CARDIOGENIC SHOCK - DOPAMINE

Dopamine action: dopaminergic [D_1 & D_2] + weaker adrenergic β_1 + very weak α receptor agonist.

* The D_1 receptors in renal & mesenteric blood vessels are the most sensitive; IV infusion of low dose of DA dilates these vessels [by raising intracellular

cAMP]. Increased renal flow negs O₂A. In addⁿ.
DA exerts natriuretic effect through D₁ receptors in
proximal tubular cells

Moderately high doses produces a positive inotropism.
[direct β_1 & D₁ action + that due to NA release],
but little chronotropic effect in heart.
Vasoconstriction [α , action] occurs only when large
doses are infused.]

* At clinically employed doses, it raises CO and systolic
BP with little effect in diastolic BP.

→ Dopamine is used in patients of cardiogenic
shock / septic shock & acute heart failure where
it increases BP & urine outflow. It is administered
by IV infusion [0.2 - 1 mg/min] which is regulated
by monitoring BP & rate of urine information.

Ⓐ RATIONALE FOR COMBINING ADRENALINE WITH LIGNOCAINE.

Addition of a vasoconstrictor like Adr has several
advantages:-

- Prolongs duration of action of Local Anesthetic
Lignocaine by slowing rate of removal from local site
into circulation; contact time of lignocaine with
nerve fibre is prolonged.
 - Enhances intensity of nerve block
 - Reduces systemic toxicity of lignocaine; rate of
absorption & sed & metabolism keeps plasma
concn lower.
 - Provides more bloodless field for surgery
- [Also, lignocaine 2% with Adr 1:80000 in 1.5ml cartridge.
for dental anesthesia]

[As local vasoconstrictor (Adr) 1 in 2,00,000 to 1 in 8000 added to lignocaine]

⑤ USES AND ADVERSE EFFECTS OF ADRENALINE.

* Adverse effects & contraindications.

Transient restlessness, headache, palpitation, anxiety, tremor & pallor may occur after S.C / IM injection of Adr.

* Hazards of large doses or inadvertent IV injection of Adr are marked rise in BP leading to cerebral hemorrhage, ventricular tachycardia / fibrillation, angina, MI.

* Adr is contraindicated in Hypertensive, Hyperthyroid & angina patients.

* Adr should not be given during anaesthesia with halothane (risk of magnesium) and to patients receiving β blockers (marked rise in BP can occur due to unopposed α action).

Actions of Adr

The peripheral actions of Adr in most tissues have been clearly differentiated into those mediated by α or β receptors depending on predominant receptor type present in a given tissue.

[Adr : $\alpha_1 + \alpha_2 + \beta_1 + \beta_2 + \text{weak } \beta_3 \text{ action}$]

α - Actions

- * Constriction of arterioles & veins $\rightarrow$ rise in BP.
[$\alpha_1 + \alpha_2$]
- * Heart : little action
- *
- * Contraction of radial muscles of iris $\rightarrow$ mydriasis (α_1), used by scopolamine.
- * Intestinal relaxation, contraction of sphincters
- * Bladder trigone, prostate - contraction (α_1)
- * Uterus contraction (α_1)
- * Neuromuscular transmission facilitated,
 $\uparrow$ ACh release
- * Insulin secretion inhibited (α_2) (dominant)
- *
- * Renin release $\downarrow$ (α_2)
- * Male sex organs - ejaculation (α_1)
- * Salivary gland - $\downarrow$ IgA, H_2O secretion (α_1)

B - Actions :

- * Dilation of arterioles & veins $\rightarrow$ fall in BP (β_2).
- * Cardiac stimulation (β_1), $\uparrow$ rate, Force & conduction velocity.
- * Bronchodilation (β_2)
- * No effect on iris, slight relaxation of ciliary muscle, enhanced aq. secretion.
- * Intestinal relaxation.
- * Detrusor-relaxation (β_2, β_3)
- * Relaxation (β_2)
- * Active state - prolonged in fast contracting muscle, abbreviated in slow contracting muscle; tremors (β_2)
- * Augmented insulin (mild) & glucagon secretion (β_2)
- * Liver glycogenolysis (β_2)
 - $\rightarrow$ hyperglycemia
- Muscle - glycogenolysis (β_2).
 - $\rightarrow$ hyperlactacidemia.
- Fat - lipolysis ($\beta_1 + \beta_2 + \beta_3$)
 - $\rightarrow$ $\uparrow$ sed $\frac{1}{2}$ FFA calorogenesis.
- * Renin release $\uparrow$ (β_1) dominant
- * Pyloric secretion.

* Adrenergic nerve -
inhibits NA release
terminals

* ADH secretion from
post-hypothalamus (PB,
)
* Facilitates NA release
(mild action).

ANTIPLATELETS DRUGS